Su1286 Differences Between Community and Academic Cohorts of Patients With Chronic Hepatitis B (CHB) in the Development of Hepatocellular Carcinoma (HCC)

G A A b st ra ct s CI = 19%-27%) for patients receiving only supportive care, 39% (95% CI = 32%-46%) for those receiving liver-directed palliative therapy, 61% (95%CI = 51%-70%) for those undergoing partial hepatectomy, and 77% (95% CI = 71%-82%) for those having a liver transplantation. In multivariate analysis (Table), independent predictors for improved survival were non-White/non-Black race, palliative as well as surgical treatment. Independent predictors for poorer survival were age older than 65 and Black race (compared toWhites). Conclusions: In spite of improved opportunity for both effective palliative and curative therapies in the recent years, almost half of patients meeting Milan criteria are still not undergoing any therapy. In addition to assessing the efficacy and survival impact of current therapies, it is also important to focus on why so many patients diagnosed with HCC are not undergoing any treatment and reasons for continued existence of racial disparities. Early diagnosis through better screening protocols together with patient and physician education is crucial to achieve better outcomes. Multivariate Cox Proportional Hazards Model Assessing Factors Associated with Survival